A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world

BACKGROUND: Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib for IPF has been previously proven in the INPULSIS(®) and INPULSIS-On(®) trials. The aim of our study was to clarify t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Transl Med
Päätekijät: Nakamura, Masayuki, Okamoto, Masaki, Fujimoto, Kiminori, Ebata, Tomohiro, Tominaga, Masaki, Nouno, Takashi, Zaizen, Yoshiaki, Kaieda, Shinjiro, Tsuda, Tohru, Kawayama, Tomotaka, Hoshino, Tomoaki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AME Publishing Company 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6614312/
https://ncbi.nlm.nih.gov/pubmed/31355229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.05.33
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia